Drugmakers now have wonkier than usual technical draft recommendations from the Centers for Medicare and Medicaid Services on the agency’s process to calculate and pay mandatory rebates if the companies raise the price of certain drugs more rapidly than the annual inflation rate.
On the floor, U.S. Senator John Cornyn (R-TX) discussed his bipartisan Affordable Prescriptions for Patients Act, which passed unanimously out of the Senate Judiciary Committee last Congress and would help lower drug prices by preventing bad actors’ anti-competitive use of patents to block generic and biosimilar competition from coming to market. Excerpts of Sen. Cornyn’s